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Activation of RhoA/Rho kinase leads to growth cone collapse and neurite retraction. Although 
RhoA/Rho kinase inhibition has been shown to improve axon regeneration, remyelination and 
functional recovery, its role in neuronal cell death remains unclear. To determine whether 
RhoA/Rho kinase played a role in neuronal death after injury, we investigated the relationship 
between RhoA/Rho kinase and cytosolic phospholipase A2 (cPLA2), a lipase that mediates 
inflammation and cell death, using an in vitro neuronal death model and an in vivo contusive 
spinal cord injury model performed at the 10th thoracic (T10) vertebral level. We found that co-
administration of TNF-α and glutamate induced spinal neuron death, and activation of RhoA, 
Rho kinase and cPLA2. Inhibition of RhoA, Rho kinase and cPLA2 significantly reduced TNF-
α/glutamate-induced cell death by 33%, 52% and 43%, respectively (p < 0.001). Inhibition of 
RhoA and Rho kinase also significantly down-regulated cPLA2 activation by 66% and 60%, 
respectively (p < 0.01). Furthermore, inhibition of RhoA and Rho kinase reduced the release of 
arachidonic acid, a downstream substrate of cPLA2. The immunofluorescence staining showed 
that ROCK1 or ROCK2, two isoforms of Rho kinase, was co-localized with cPLA2 in neuronal 
cytoplasm. Interestingly, co-immunoprecipitation (Co-IP) assay showed that ROCK1 or ROCK2, 
bonded directly with cPLA2 and phospho-cPLA2. When the Rho kinase inhibitor Y27632 was 
applied in mice with T10 contusion injury, it significantly decreased cPLA2 activation and 
expression, and reduced injury-induced apoptosis in the lesion area. Taken together, our results 
reveal a novel mechanism of RhoA/Rho kinase-mediated neuronal death through regulating 
cPLA2 activation.  
 








A spinal cord injury (SCI) refers to any damage to the spinal cord that is caused by a trauma 
instead of disease [1]. SCI includes a primary mechanic injury followed by a much more 
complicated secondary injury process involving inflammation, oxidation and excitotoxicity [1]. 
Both injuries inevitably cause neuronal and glial cell death at and surrounding the site of injury, 
which contributes to long-lasting functional deficits [1].  
        Rho kinase (including ROCK1 and ROCK2) is one of the AGC families of serine-threonine 
kinases [2]. Rho kinase is a downstream effector of the small GTPase RhoA, which is a major 
cytoskeleton regulator. The RhoA/Rho Kinase signaling pathway contributes to diverse neuronal 
functions ranging from cell migration, survival, axonal guidance, to axonal regeneration [3-5]. 
This pathway has also been shown to play an important role in the pathophysiology of SCI 
[6,4,7]. For example, upregulation of RhoA was observed after SCI [8]. Rho kinase has also 
been shown to be involved in cell death and signaling [9].  It not only regulates morphological 
apoptotic events such as membrane blebbing [10], fragmentation and phagocytosis of apoptotic 
cells [11-13],  but also mediates production of reactive oxygen species and inflammatory 
cytokines [14]. However, the mechanism by which RhoA/Rho kinase mediates cell death 
remains unclear. 
        Phospholipase A2 (PLA2) is a family of enzymes that hydrolyze the acyl bond of 
glycerophospholipids at the sn-2 position to produce free fatty acid and lysophospholipids [15-
17]. The metabolic products of PLA2s play important roles in cell death [18]. Among different 
PLA2 isoforms, cytosolic PLA2 (cPLA2) participates in mediating inflammation and cytotoxicity 
[17]. A main product of cPLA2 is arachidonic acid (AA)[19], which can give rise to eicosanoids 
that mediate inflammation, necrosis and apoptosis [19,20]. Our prior research has demonstrated 
significant increases of PLA2 activity and cPLA2 expression following SCI [21,22]. cPLA2 is 
highly expressed in neurons, axons and glial cells and peaked at day 1 in axons, day 3 in glial 
cells, and day 7 in neurons after SCI [21]. Activation of cPLA2 is sufficient to induce spinal cord 
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neuronal death in vitro. Genetic ablation of cPLA2 reduces cell loss and tissue damage, and 
improves behavioral recovery after SCI [22]. 
        After contusive spinal cord injury, neurons and glial cells die acutely caused by primary 
mechanical force and later by multiple injury mechanisms such as inflammation, oxidation and 
excitotoxicity [23,24]. A previous study showed that apoptosis occurred in neurons in the lesion 
area between 4 to 24 hours post-injury and reached the peak at 8 hours [25]. The apoptosis in 
glial cells were found at all stages from 4 hours to 14 days, with a maximum presence in lesion 
area 24 hours after injury [25]. This study indicates that neuronal and glial cell apoptosis 
occurred at the lesion site within 1 day after contusive SCI. 
        In the present study, we sought to determine potential mechanisms of RhoA/Rho kinase-
mediated cell death in both in vitro and in vivo SCI models. We examined the relationship 
between RhoA/Rho kinase and cPLA2 activation in which spinal cord neuronal death was 
induced by  a combined insult of TNF-α and glutamate, the two major mediators of damage in 
the progression of secondary SCI. Then we confirmed the RhoA/Rho kinase modulation on 
cPLA2 activationby injecting Y27631, an inhibitor of Rho kinase, into the lesion site of a T10 
contusive SCI produced by the Louisville System Injury Apparatus (LISA) device in adult mice.  
 
Materials and Methods 
Reagents 
TNF-α (Sigma-Aldrich, T5944), L-glutamic acid (Sigma-Aldrich, G1626), CT04 
(Cytoskeleton. Inc., Rho inhibitor I), Y27632 (Enzo Life Sciences, ALX-270-333), arachidonyl 
trifluoromethyl ketone (ATK) (Cayman Chemical, 62120). 
 
Rats and mice 
    Sprague-Dawley (SD) E13 pregnant rats and C57BL/6J mice (12 weeks, 18-24g) were 
purchased from Charles River (USA). Rats and mice were housed at Indiana University School 
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of Medicine Laboratory Animal Resource Center. All surgical and animal handling 
procedures were performed as approved under the Guide for the Care and Use of 
Laboratory Animals (National Research Council) and the Guidelines of the Indiana 
University School of Medicine Institutional Animal Care and Use Committee. 
 
Cell culture and treatments 
    Rat primary spinal cord neurons were obtained from SD rat embryonic E15 pups according to 
a previously established protocol [26]. In brief, E15 rat spinal cords were isolated and placed in 
L15 medium. Meninges were carefully removed and spinal cords were cut into small pieces, 
dissociated by incubation in 0.05% trypsin/EDTA 15 min at 37oC and triturated every 5 min. The 
dissociated cells were washed with and triturated in 10% heat-inactivated fetal bovine serum 
(FBS), 5% heat-inactivate horse serum (HS), 2mM glutamine-DMEM (all from Gibco, USA) and 
cultured in 10 cm plate for 30 min at 37oC to eliminate glial cells and fibroblasts. The 
supernatant which contains neurons was collected and seeded on poly-L-lysine coated 48 well 
plates and incubated in a humidified atmosphere containing 5% CO2 at 37oC with 10% FBS + 5% 
HS + 2 mM glutamine DMEM. After 16 hours, medium was replaced with Neurobasal medium 
with 2% B27 (Gibco), 1% N2 (Gibco) and 2 mM glutamine. On day 3, 5 µM cytosine-β-D-
arabinofuranoside (Sigma-Aldrich) was added for 24 hours to inhibit glia cell proliferation. With 
this culture protocol, a purity of greater than 94% spinal cord neuronal population was obtained 
on day 7. All experiments were performed between 7-10 days. Hela cells (ATCC, USA) were 
cultured in 10% FBS-DMEM (Gibco). 
 
Cell death assessment   
    A non-radioactive cytotoxicity assay (Promega, USA) was used to measure lactate 
dehydrogenase (LDH), a stable cytosolic enzyme that is released upon cell lysis. Released LDH 
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can convert tetrazolium salt into a red formazan product. On day 7 in culture, the medium was 
replaced by fresh medium and the neurons were treated by TNF-α, glutamate or combined 
TNF-α and glutamate for 24 hours. In the inhibition groups, the inhibitors, CT04, Y27632 and 
ATK pretreated neurons at 40 min before the application of TNF-α, glutamate or the 
combination. Fifty microliters of supernatant were removed for LDH assay following the vendor’s 
instruction. The LDH level was measured by a 96 well plate reader (1420 multilabel counter, 
PerkinElmer) at 490 nm wavelength. 
    Propidium iodide (PI)/Hoechst staining was also used as a measurement of cell death. 
Hoechst 33342 (Sigma-Aldrich) 5 μg/ml was added to the cells at 37oC for 15 min to label all cell 
nuclei, followed by incubation with 5 µg/ml PI (Sigma-Aldrich) at room temperature for 10 min to 
stain dead cell nuclei. After staining, the medium was removed and cells were washed with 
0.01M PBS, followed by 10 min of 4% PFA for cell fixation. The fixed cells were then washed 3 
times with PBS and ready for imaging using an Olympus IX71 inverted fluorescence microscope 
(Olympus America Inc.). Three wells were assigned as one group. The images of three views 
per well were taken. The blue stained cells and the red stained cells were counted using ImageJ 
software (NIH) and the percentage of death cell was calculated. 
 
Immunofluorescence staining 
    Immunofluorescence staining was performed as previously described [27]. Briefly, spinal cord 
neurons on coverslips on day 7 were fixed by 4%PFA followed by washing with 0.01M PBS, 
blocking 1 hour with 5% goat serum-0.3% Triton X-100-PBS, and staining with anti-rabbit βIII 
tubulin(1:1000, Cell Signaling, USA), anti-mouse NeuN (1:100, EMD Millipore, USA), anti-rabbit 
ROCK1 (1:100) or anti-rabbit ROCK2 (1:100, Santa Cruz, USA) [27], anti-mouse cPLA2 (1:50, 
Santa Cruz, USA)  antibodies at 4oC overnight. The next day, the cells were washed 3 times 
with PBS. The anti-rabbit FITC (1:200) or anti-mouse rhodamine (1:200) secondary antibodies 
(ICN Biochemicals, Aurora, OH) were applied 1 hour at room temperature followed by 3 PBS 
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washes. The coverslips were mounted by Vectashield mounting medium containing DAPI 
(Vector Laboratory, Inc.).  Images were taken with Olympus BX61 fluorescence microscope 
(Olympus America Inc.) or by phase invert microscope (Olympus CK2, Japan) at 20x, 40x, and 
60x magnifications. 
 
Western blot analysis   
    Western blotting analysis was performed as described previously [26]. Whole cell lysates 
were prepared with RIPA buffer and protease/phosphatase inhibitors cocktail (Thermo 
Scientific). Protein concentration was measured with a Bio-Rad protein assay (Bio-Rad). The 
amount of 60 μg protein was loaded and separated by 12% or 8% SDS-polyacrylamide gel and 
transferred onto polyvinylidene difluoride membrane (PVDF) (Li-COR Biosciences). After 1 hour 
blocking with LI-blocking buffer (LI-COR Biosciences), the membranes were incubated with 
primary antibodies overnight at 4oC. Rabbit antibodies specific for phospho-cPLA2 (1:800), RhoA 
(1:1000), and cleaved-caspase 3 (1:800) were from Cell Signaling Tech. Inc., and ROCK1 and 
ROCK2 (1:800), GAPDH (1:2000) were purchased from Santa Cruz Biotech. Inc. Mouse 
antibody specific for cPLA2 (1:100) was from Santa Cruz Biotech, Inc. and β-tubulin antibody 
(1:2000) was from Sigma-Aldrich. Following incubation, membranes were washed and 
incubated with a secondary fluorescence conjugated antibodies, IRDye800, IRDye680 anti-
rabbit or IRDye800, IRDye680 anti-mouse (1:10000, Rockland Immunochemicals) for 1 hour at 
room temperature. After removal of secondary antibody solution via subsequent PBS washes, 
the membranes were scanned using a LI-COR Odyssey infrared scanner. The images were 
captured and the densitometries were measured and analyzed by Image Studio2.0 software 
(LICOR).  
 
Measurement of AA release    
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    Arachidonic acid was measured by an AA ELISA kit (Bluegene Biotech, China) according to 
the manufacturer’s instructions. Briefly, 150 µL fresh 2%B27-1%N2-2mM Glutamine-Neurobasal 
medium was replaced in 48 well plates with cultured neurons. 2.5 µM ATK, 5 μM Y27632 and 
4.0 µg/ml CT04 were applied to the medium for 40 min, followed by TNF-α and glutamate 
treatment for 16 hours. Next, 100 µL supernatant was collected for detection of released AA by 
ELISA. Following the given instructions, the densitometry of the reaction was measured by a 96 
well plate reader (1420 multi-label counter, PerkinElmer) on wavelength 450 nm. 
 
RhoA activity Assay  
    Following the manual for a RhoA activation assay Biochem kit (Cytoskeleton, Inc.), 600 μg 
whole cell lysate was incubated with 50 μg rhotekin-RBD beads at 4oC, 1 hour. The beads were 
then washed with wash buffer and treated by 20 μl 2x Laemmli sample buffer (Bio-Rad, CA, 
USA) then denatured at 95oC for 5 min. The samples were then ready for Western blot assay. 
 
Co-immunoprecipitation assay  
    The assay was performed using a Universal Magnetic Co-IP kit (Active Motif Inc.) according 
to manufacturer’s instructions. In brief, 500 μg cell lysate was combined with 5 μg ROCK1 or 
ROCK2 antibody, and underwent shaking at 4oC for 4 hours. 25 μl protein G Magnetic Beads 
was then added in the reaction and incubated for 1 hour at 4oC. Next, the tube with the beads 
was placed on a magnetic stand to pellet beads. The supernatant was carefully removed and 
500 μl Co-IP/wash buffer was added to wash the beads 4 times. Next, the bead pellet was 
suspended in 20 μl of 2xLaemmli sample buffer and heated at 95oC for 5min, the samples were 
ready for Western blot assay. 
 
T10 contusive spinal cord injury and treatment  
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    Fifteen C57BL/6J mice (12 weeks, 18-24g) were divided into 3 groups: sham with 
laminectomy only, T10 SCI with saline, and T10 SCI with Y27632, an inhibitor of Rho kinase. 
The mouse was anesthetized with a mixture of 17.2 mg/ml Ketamine, 0.475 mg/ml Xylazine and 
0.238 mg/ml Acepromazine. The spinal cord contusive injury was performed at the 10th thoracic 
(T10) vertebral level with the LISA device at a displacement of 0.5 mm from the dorsal surface 
of the spinal cord, and a velocity of 1.00 M/Sec as previously described [28]. A total of 4 
microinjections of Y27632 (1 microliter 100 µM/injection) were made into the spinal cord 
immediately after the injury in bilateral and rostrocaudal directions according to the following 
coordination: 1.0 mm rostrocaudally from the injury epicenter, 0.24 mm laterally from the midline 
and 0.5 mm ventrally from the dorsal cord surface.  After the injury and Y27632 injection, the 
muscles and skin were closed in layers and the animal received intraperitoneal injection of 1 ml 
saline. After 24 hours, mice were re-anesthetized and perfusion with 0.01M PBS and 1 cm 
spinal cord segment containing the lesion center was harvested. The protein was isolated and 
analyzed by Western Blot assay. 
 
Statistical Analysis 
    One-way ANOVA was used to determine statistical significance between multiple groups and 
a Student’s t-test was utilized to determine significant value differences between 2 groups. Data 
are reported as mean ± s.e.m. A p value < 0.05 was considered statistically significant. 
 
Results 
Combined insults of TNF-α and glutamate induced neurotoxicity in vitro.  
To mimic secondary neuronal injury after the initial spinal cord trauma, we established an in 
vitro spinal neuronal injury model treated with an inflammatory mediator TNF-α or/and an 
excitatory mediator glutamate. Rat spinal cord neurons at 7 days of culture in our preparation 
reached a near pure population of spinal cord neurons (Fig.1 a). Using these neurons, we first 
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investigated the effect of TNF-α on spinal neuronal death. We tested different concentrations of 
TNF-α from 20 to 200 ng/ml and different treatment time points from 24 to 72 hours. Regardless 
of the concentration or treatment time point, TNF-α alone did not induce neuronal death (data 
not shown). We then tested glutamate neurotoxicity at a concentration range between 3 and 
200 μM for 24 hours. We found that 5 μM glutamate was the minimum concentration sufficient 
to induce cell death (p < 0.05). The glutamate excitotoxicity peaked at 50 μM, and increasing 
concentration of glutamate to 100 or 200 μM did not induce further increasing of cell death (data 
not shown).  Next we combined TNF-α with a sub-lethal dose of 3 μM glutamate. We found that 
TNF-α at 50 and 100 ng/ml significantly increased spinal neuronal death by 45% and 51%, 
respectively. When combined with 5 μM of glutamate, TNF-α induced additional 27% (50 ng/ml) 
and 21% (100 ng/ml) neuron death (Fig. 1 b, c). These data indicated that TNF-α potentiated 
glutamate neurotoxicity on rat spinal cord neurons, which are in agreement with other reports 
[29,30]. 
 
TNF-α and glutamate induced activation of both RhoA/Rho kinase and cPLA2  
To dissect out the mechanism of neurotoxicity induced by TNF-α and glutamate, we 
examined RhoA/Rho kinase and cPLA2 activities. The data showed that, following TNF-α and 
glutamate treatment, the active form of RhoA (RhoA-GTP), which was precipitated by Rhotekin 
beads, was increased significantly at 5 minutes (Fig. 2 a, c), decreased at 10 and 30 minutes 
and elevated considerably by 3 hours post-treatment. Meanwhile, Rho kinase (ROCK1, ROCK2) 
and cPLA2 were activated as well at 10 min and 30 min and remained highly elevated up to 3 
hours post-treatment (Fig. 2 b, d). These results indicate that TNF-α and glutamate treatment 
activated RhoA, Rho kinase and cPLA2. 
 
Inhibition of RhoA, Rho kinase and cPLA2 activation reduced spinal cord neuronal death 
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To investigate whether RhoA, Rho kinase and cPLA2 are involved in neuronal death, we 
applied a RhoA inhibitor CT04, a Rho kinase inhibitor Y27632, and a cPLA2 inhibitor arachidonyl 
trifluoromethyl ketone (ATK), to spinal cord neurons at 40 min prior to the combined 
administration of TNF-α and glutamate. We found that with combined TNF-α and glutamate 
treatment, neurons showed morphological degenerative changes including neurite retraction 
and soma condensation as compared to the control; such changes, however, were effectively 
blocked by treatments of ATK, Y27632 or CT04, respectively (Fig. 3 a-e).  LDH releasing assay 
showed that ATK, Y27632 and CT04 significantly decreased cell death by 19%, 18% and 16% 
(p < 0.05) (Fig. 3 f). Likewise, Propidium iodide (PI)/Hoechst staining showed a significant 
increase in neuronal death after receiving TNF-α and glutamate treatment as compared to the 
non-treated; such death, however, were significantly reduced by 43%, 52% and 33%, 
respectively, by treatments of ATK, Y27632 or CT04 (Fig. 3 a-1-e-1, g). These data indicate that 
RhoA, Rho kinase and cPLA2 activation contribute to neuronal pathology and death induced by 
TNF-α and glutamate.  
 
RhoA or Rho kinase inhibition down-regulated cPLA2 activation and AA release 
To investigate whether RhoA or Rho kinase regulated cPLA2 activation, inhibitors of Rho 
kinase (Y27632) and RhoA (CT04) were administered and phospho-cPLA2 was analyzed by 
Western blot. The data showed that phospho-cPLA2 significantly decreased by 60% and 66% 
by these inhibitors, respectively (p < 0.01; Fig. 4 a, b). Moreover, the cPLA2 inhibitor, ATK, also 
decreased activation of cPLA2 by 38% (p <0.01; Fig 4 a, b). To confirm these results, we further 
measured the levels of AA, which is a primary product of cPLA2. The data showed that inhibiting 
either Rho kinase or RhoA decreased AA release by 26% and 26%, respectively (p <0.01; Fig.4 
c).  Additionally, direct inhibition of cPLA2 reduced AA release by 30% (p <0.01; Fig. 4 c). These 




ROCK1 and ROCK2, two isoforms of Rho kinase, co-localized and bound with cPLA2 
Since inhibition of RhoA and Rho kinase down-regulated cPLA2 activation, we then asked 
whether Rho kinase had the same distribution as cPLA2 and whether it could directly interact 
with cPLA2.  We stained spinal cord neurons with Rho kinase (ROCK1 or ROCK2) and cPLA2 
antibodies and immunofluorescent secondary antibodies. The images showed that ROCK1 or 
ROCK2 existed in cytoplasm, the same distribution as cytosolic PLA2 (cPLA2) (Fig. 5 a). Next, 
we used a co-immunoprecipitation assay to address the second question and found that both 
ROCK1 and ROCK2 directly bound with either p-cPLA2 or cPLA2 in two cell types, i.e., spinal 
cord neurons and Hela cells (Fig. 5 b). 
 
Rho kinase inhibitor Y27632 downregulated cPLA2 expression and activation following 
T10 contusive SCI in adult mice 
Finally, we confirmed Rho kinase inhibition on cPLA2 expression and activation in vivo in a 
mouse T10 contusive SCI model using a Louisville Injury System Apparatus (LISA) impactor. 
This model has been used reliably in our previous studies [28]. It produces consistent and 
reliable injuries due to its precise determination of the “0” point of the spinal dorsal surface by a 
laser sensor and precise determination of displacement parameters of injury. Immediately after 
the injury, four injections of 1 μl Y27632 (100µM), were made into the rostral and caudal host 
spinal cord on both sides close to the lesion epicenter. At 24 hours post-injury, 1 cm of spinal 
cord segment containing the injury epicenter was harvested and analyzed by Western Blot. The 
data showed that at 24 hours post-SCI, the expression of Rho kinase and cPLA2 was 
significantly increased. In addition, the apoptotic cell death marker cleaved-caspase 3 was also 
remarkably increased. Notably, Y27632 administration significantly inhibited expression of Rho 
kinase, cPLA2, and phorspho-cPLA2. As anticipated, cleaved-caspase 3 was also significantly 
reduced (Fig. 6A, B). These data indicate that Rho kinase regulates cPLA2 activation and 





    During the secondary SCI process, inflammation, glutamate excitotoxicity and free radical-
mediated oxidative stress are major events that contribute to cell death [31,32]. Glutamate is a 
common mediator of excitotoxicity in the CNS disease and trauma [33]. The inflammatory 
cytokine TNF-α is another important mediator which participates in inflammatory and cell death 
post-SCI [34,35,24].  Recently, both in vitro and in vivo studies demonstrated that TNF-α does 
not induce neuronal death on its own [30,36]; however, it can potentiate glutamate excitotoxicity 
by inhibiting glutamate uptake [37], and elevating NF-кB [37,38] and cFOS activation [36]. Our 
data are consistent with these reports. Regardless of the dose (up to 200ng/ml) or duration of 
treatment (up to 72 hours), TNF-α did not induce neuronal loss in the present study. However, 
when combined with a sub-lethal dose of glutamate, TNF-α significantly increased neuronal 
death. These data indicate that TNF-α and glutamate act synergistically to induce neuronal 
death in this model.  
        Previous studies have demonstrated that TNF-α or glutamate can activate RhoA and Rho 
kinase [39-41].  RhoA is an essential component of the excitotoxicity pathway, and is sufficient 
to induce the activation of such pathway [42].  Rho kinase also has been shown to be important 
in the regulation of cell death [9]. Rho kinase-phosphorylated myosin light chain which 
stimulates actomyosin contractility that controls apoptosis cell membrane blebbing [11], nuclear 
disintegration [12] and cellular fragmentation [11]. Rho kinase activation also stimulates 
phosphatase and tensin homologue (PTEN) and inhibits insulin receptor substrate 1 (IRS1) 
signaling to inactivated Akt which plays an important role in cell survival[43,44]. In addition, 
ROCK2 can promote apoptosis by increasing ezrin phosphorylation, which increases Fas, death 
receptor clustering and expression[45]. Furthermore, Rho kinase mediates inflammatory cell 
infiltration and cytokine production [46,47], and mediates reactive oxygen species (ROS) 
production [48]. Our data also demonstrate that RhoA/Rho kinase activation is involved in cell 
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death and that inhibiting RhoA or Rho kinase activation significantly reduces neuronal cell death 
induced by TNF-α and glutamate.         
        cPLA2 is an 85kDa protein enzyme that preferentially produces arachidonic acid (AA) by 
hydrolyzing the sn-2 position of glycerophospholipids[49]. Our lab has previously shown that 
cPLA2 activation increased as early as 8 hours and peaked at 7 days post-SCI [22,21]. 
Activation of cPLA2 by its activator, ceramide-1-phosphate or A23187, is sufficient to induce 
neuronal death, whereas cPLA2 inhibition reduces cell loss in vitro[22]. Following acute SCI, 
cPLA2 inhibition reduces inflammation, cell death, tissue damage and improves functional 
recovery [22]. TNF-α or glutamate have also been shown to activate cPLA2 in several non-
neuronal cell types [50,51]. Our results demonstrate that cPLA2 can be activated by combined 
stimulation of TNF-α and glutamate, and that inhibition of cPLA2 significantly decreases 
neuronal death. These results further confirm that cPLA2 activation can induce neuronal death. 
        Recent studies indicate that cPLA2 can be activated by two distinct pathways, one involves 
Ca2+, and another involves multiple kinases. Elevated Ca2+ binds with cPLA2 amino-terminal C2 
domain then activates cPLA2 [52]. Multiple kinases including p42/p44 mitogen-activated protein 
kinase (ERK1/2 MAPKs) [53], p38 MAPK and MNK1-related protein kinases [54,55] 
phosphorylate cPLA2 at serine 505 or 727. Other studies showed that N-terminal kinase (JNK) 
also activates cPLA2 [56]. After activation, phospho-cPLA2 translocate from the cytosol to the 
nuclear envelope, endoplasmic reticulum and Golgi membranes [57,58] and hydrolyzes 
glycerophospholipids to produce free fatty acids and lysophospholipids [19]. In vivo research 
showed that ERK1/2 and phospho-cPLA2 were highly co-expressed in neurons, degenerated 
axons and glial cells at 24 hours post-SCI. U0126, an ERK1/2 inhibitor decreased ERK1/2 
activation and subsequently reduced cPLA2 activation [22]. RhoA is upstream of not only p38, 
but also ERK1/2. Active RhoA increases ERK1/2 and p38 activation and consequently cPLA2 
phosphorylation, mainly by ERK1/2 [59]. Since Rho kinase is the main downstream substrate of 
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RhoA, we hypothesized that Rho kinase regulates cPLA2 activation which was confirmed by the 
present study. Importantly, our in vitro and in vivo results demonstrated, for the first time, that 
inhibition of RhoA or Rho kinase remarkably down-regulated active phosphorylated cPLA2. 
Moreover, the two isoforms of Rho kinase, ROCK1 and ROCK2 co-localized and directly bound 
with cPLA2 and phospho-cPLA2. Inhibition of RhoA and Rho kinase significantly reduced AA 
release supporting the notion that RhoA/Rho kinase regulates cPLA2 activation. These data 
collectively indicate that RhoA and Rho kinase directly regulate cPLA2 activation and 
subsequently cell death. However whether Rho kinase can directly phosphorylate cPLA2 
remains unclear and needs to be further investigated.  
       In summary, the current study has revealed a potential mechanism of neuronal cell death 
induced by TNF-α and glutamate, which is summarized in the schematic diagram of Figure 7. 
The combined insult of TNF-α and glutamate activates RhoA and Rho kinase and consequently 
activates cPLA2. Active cPLA2 then translocate from the cytosol to the cell and organelle 
membranes and hydrolyzes glycerophospholipids to produce AA and eicosanoids, and induces 
caspase activation and cell death. Thus, our study shows, for the first time, the mechanistic link 
between RhoA/Rho kinase activation, cPLA2 activation, and cell death.  
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Fig. 1  Establishment of spinal cord neuronal injury model in vitro. (a) Highly purified spinal cord 
neurons stained with a neurite marker βIII tubulin and neuronal marker NeuN, counterstained 
with a fluorescent nuclear marker DAPI. (b) Bright-field images show spinal cord neurons that 
received no treatment (control), or treatment for 24 hour with 50 ng/ml TNF-α,  3µM glutamate, 
or a combination of the two. Arrows show the live cells and arrowheads show the dead cells. (c) 
Neuronal death measured by the LDH assay. Values are means ± s.e.m. (n = 4).  p < 0.01 
versus control. Bar in A & B = 50 μm. 
Fig. 2  TNF-α and glutamate induced activation of RhoA, Rho kinase and cPLA2. (a, b) Western 
blot analysis showed that the activation of RhoA (a), Rho kinase and cPLA2 (b) were 
significantly increased. (c, d) Densitometric quantification of RhoA, Rho kinase, and cPLA2 
activation. Data were expressed as fold change compared to the control group. Values are 
means ± s.e.m. (n = 4). * p < 0.05, ** p < 0.01, ***p < 0.001.  
 
Fig. 3  Inhibition of RhoA, Rho Kinase, and cPLA2 decreased neuronal death induced by TNF-α 
and glutamate. Spinal cord neurons were pretreated with ATK, Y27632, and CT04 at 40 
minutes prior to the application of TNF-α and glutamate.  After 24 hours, phase contrast images 
of neurons were taken (top row) and cells were stained by Propidium iodide (PI, red) and 
Hoechst (blue) (bottom row) in healthy neurons (a, a1) or neurons challenged with TNF-α and 
glutamate (b-e, b1-e1). In the latter condition, cultured were treated with ATK, a cPLA2 inhibitor 
(c, c1), Y27632,  a ROCK1/2 inhibitor (d, d1), and CT04, a RhoA inhibitor (e, e1). Live neurons 
with clear cell bodies (top row) and blue Hoechst nuclear staining (bottom row) can be clearly 
seen (red and white arrows, respectively). Dead neurons with degenerating cell bodies (top row) 
and red PI nuclear staining (bottom row) can also be appreciated (red and white arrowhead).  
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Quantitative data show cell death in fold change measured with LDH releasing (f), and in 
percent change measured by the PI+ and Hoechst+ cells (g). Values are means ± s.e.m. (n = 4), 
* p < 0.05, ** p < 0.01, ***p <0.001, Bars = 50 μm. 
 
Fig. 4  RhoA/Rho kinase regulated cPLA2 activation. (a) The inhibitors of RhoA (CT04), Rho 
kinase (Y27632), and cPLA2 (ATK) down-regulated cPLA2 activation induced by TNFα and 
glutamate. (b) The quantification data of active cPLA2 and GAPDH. (c) The release of AA, the 
main downstream product of cPLA2, was significantly reduced by ATK, Y27362 and CT04 
(ELISA). Values are means ± s.e.m (n = 3). Data are expressed as fold change compared with 
the control group, **p < 0.01, ***p<0.001.  
 
Fig. 5  Rho kinase (ROCK1/ROCK2) was co-localized and bound directly with cPLA2. (a) The 
spinal cord neurons were stained with ROCK1, ROCK2, and cPLA2 antibodies and the images 
were taken at 60x magnification. Both ROCK1 or ROCK2 and cPLA2 localized in cytoplasm. (b) 
Whole cell lysates of spinal cord neurons and Hela cells were immunoprecipitated with ROCK1, 
ROCK2 antibodies then immunobloted by phospho-cPLA2 and cPLA2 antibodies. The rabbit IgG 
antibody was used as a negative control. The data showed p-cPLA2/cPLA2 bound directly with 
ROCK1 or ROCK2. Bar=10 µM. 
 
Fig. 6 Rho kinase inhibitor, Y27632, downregulated cPLA2 and phospho-cPLA2 and reduced 
apoptosis cell death in mice T10 contusion model. (a) The Rho kinase inhibitor,Y27632, 1µl of 
100µM was injected in mice T10 spinal cord/site around lesion area immediately after contusion 
injury. The spinal cords which contained lesion area were isolated post injury 24 hours and 
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analyzed by Western blot. (b) The quantitative data of densitometry. Values are means ± s.e.m. 
(n = 5). Data are expressed as fold change compared with the control group, *p < 0.05， ** 
p<0.01. 
 
Fig. 7  Schematic drawing illustrates the proposed mechanism of RhoA/Rho kinase and cPLA2 
activation following spinal cord injury. The combined TNF-α and glutamate insults activate 
RhoA/Rho kinase and cPLA2. The phospho-cPLA2 re-localizes to cell and organelle membrane 
to hydrolyze phospholipids to arachidonic acid (AA) and eicosanoids to induce neuronal death. 
Inhibition of RhoA, ROCK1/2, and cPLA2 with CT04, Y27632, and ATK reduces cPLA2 activation 
and neuronal death.   
 
 
 







